Biomarkers in Parkinson’s Disease is focused on the biomarker identification and development in patients with Parkinson’s Disease. As a spin-off of Biomarkers: Discovery and Development for a Diagnostic Approach to Neurodegenerative Disorders, this report focuses on the Parkinson’s Disease space featured in the parent report, highlighting several biomarker targets under investigation and the progress that has been made in the industry. With regards to employing the use of biomarkers for Parkinson’s Disease, Biomarkers in Parkinson’s Disease captures market growth of biomarkers, advantages, disadvantages, and validation techniques.
Experts interviewed in this report include:
Dr. Andrew West, Associate Professor of Neurology and Neurobiology and Co-Director, Center for Neurodegeneration and Experimental Therapeutics
Dr. Xuemei Huang, Professor and Vice Chair, Department of Neurology; Professor of Neurosurgery, Radiology, Pharmacology, and Kinesiology Director; Hershey Brain Analysis Research Laboratory for Neurodegenerative Disorders, Penn State University-Milton, S. Hershey Medical Center Department of Neurology
Dr. Andreas Jeromin, CSO and President of Atlantic Biomarkers
Also available in this report is extensive survey data exclusively conducted for this report. Illustrated by 30 figures captured in an in-depth analysis, this section features insight into targets under investigation, challenges, advantages, and desired features of future diagnostic applications.
To add even more to the robustness of this report, Insight Pharma Reports also engineered a table of clinical trial information and pipeline data from multiple databases related to Parkinson’s Disease. This table features companies, targets, clinical phases, and brief target/product descriptions.